Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study.
Servetto A, Santaniello A, Napolitano F, Foschini F, Marciano R, Mozzillo E, Cascetta P, Amato AR, Augurio MR, Maresca L, De Placido P, De Placido S, Formisano L, Bianco R. Servetto A, et al. Among authors: de placido s, de placido p. Cancers (Basel). 2021 Sep 30;13(19):4939. doi: 10.3390/cancers13194939. Cancers (Basel). 2021. PMID: 34638422 Free PMC article.
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study.
Carlomagno C, Orditura M, Pepe S, De Vita F, Romano C, Ciardiello F, Ferrara C, Martinelli E, Bianco R, Aurilio G, D'Agostino D, Tortora G, Catalano G, De Placido S. Carlomagno C, et al. Among authors: de placido s, de vita f. Am J Clin Oncol. 2006 Feb;29(1):85-9. doi: 10.1097/01.coc.0000195087.24930.e7. Am J Clin Oncol. 2006. PMID: 16462509 Clinical Trial.
Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.
Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R. Rosa R, et al. Among authors: de stefano a, de placido s. Clin Cancer Res. 2013 Jan 1;19(1):138-47. doi: 10.1158/1078-0432.CCR-12-1050. Epub 2012 Nov 19. Clin Cancer Res. 2013. PMID: 23166225
Mechanisms of lapatinib resistance in HER2-driven breast cancer.
D'Amato V, Raimondo L, Formisano L, Giuliano M, De Placido S, Rosa R, Bianco R. D'Amato V, et al. Among authors: de placido s. Cancer Treat Rev. 2015 Dec;41(10):877-83. doi: 10.1016/j.ctrv.2015.08.001. Epub 2015 Aug 8. Cancer Treat Rev. 2015. PMID: 26276735 Review.
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Formisano L, D'Amato V, Servetto A, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R. Formisano L, et al. Among authors: de placido s. Oncotarget. 2015 Sep 22;6(28):26090-103. doi: 10.18632/oncotarget.4636. Oncotarget. 2015. PMID: 26325669 Free PMC article.
398 results